Healthcare & Medical Devices Global On demand · 24-48h

Global Medical Grade Rubber Market Strategic Research Report

Global Medical Grade Rubber Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Medical Grade Rubber Market
$3.14B2025
6.3%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Synthetic Rubber, Natural Rubber

By Application: Hospital, Clinic, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: ExxonMobil, AVK GUMMI, Oomi Shima Sangyo, Dupont, Daikyo Seiko, APG Pharma, Dow, Elkem Silicones, Momentive Performance Materials, Avantor, Primasil, Saint-Gobain, Shin-Etsu Chemical, Wacker Chemie, West Pharmaceutical Services, UD Pharma Rubber Products, Sagar Rrubber, Nipro, Datwyler, Aptar Pharma, Huaren Pharmaceutical, HuaRun Technology, First Rubber Medical, Shandong Pharmaceutical Glass, Ningbo Xingya Rubber & Plastic, Jintai Industrial

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 181 pages
Market size 2025
$3.14B
Billion USD
Forecast CAGR
6.3%
2025-2032
Forecast 2032
$4.8B
Projected
Régions
5
Asia Pacific · Latin America · MEA · Europe · North America

Vue d'ensemble

Scope of the Report

The global Medical Grade Rubber market size is predicted to grow from US$ 3,140 million in 2025 to US$ 4,786 million in 2032; it is expected to grow at a CAGR of 6.3% from 2026 to 2032.

In 2024, global Medical Grade Rubber production reached approximately 720k tons, with an average global market price of around US$ 4200 per ton.

Medical-grade rubber is a broad category of elastomeric materials specifically formulated for use in medical devices, pharmaceutical packaging, and healthcare consumables, encompassing natural rubber, synthetic rubbers, silicone elastomers, and thermoplastic elastomers. Beyond conventional requirements such as elasticity, fatigue resistance, tear strength, and chemical resistance, medical-grade rubber must comply with stringent standards on biocompatibility (e.g., ISO 10993), USP Class VI, sterilization compatibility, low extractables and leachables, and low particulate levels, while maintaining stable properties under steam autoclave, ethylene oxide, gamma, or electron-beam sterilization. Typical applications include tubing and connectors in infusion and catheter systems, plungers and stoppers for syringes and vials, seals and diaphragms in blood collection and dialysis equipment, sealing interfaces in respirator masks and anesthesia circuits, O-rings and gaskets in cardiovascular and interventional devices, balloons and valve components, as well as seals, cushions, and protective covers in diagnostic instruments. Compared with general industrial rubber, medical-grade rubber requires carefully selected raw materials, tightly controlled formulations, and manufacturing in clean environments under rigorous quality systems to ensure safety and long-term reliability in contact with human tissue and pharmaceuticals.

In the value chain, the upstream segment for medical-grade rubber consists of polymer and elastomer suppliers that provide medical-grade silicone rubbers, thermoplastic elastomers (TPE/TPU), butyl and halobutyl rubbers, EPDM, nitrile, fluororubbers, and synthetic polyisoprene, along with high-purity fillers such as silica, medical talc, and spherical silica, as well as medical-grade masterbatches, plasticizers, crosslinkers, and stabilizers. Some applications also require medical-grade stainless steel inserts, reinforcing fibers, and engineering plastics as substrates for overmolding or composite structures. The midstream comprises compounders and manufacturers of medical rubber products that operate in cleanroom environments, performing compounding, molding, extrusion, and post-curing to produce medical tubing, stoppers, plungers, O-rings, diaphragms, respirator masks, balloons, and valve components, often including rubber-to-metal or rubber-to-plastic bonded parts and multi-material assemblies; many also offer washing, sterilization, and sterile packaging. Downstream customers are a broad range of medical device and consumable manufacturers—including producers of infusion and injection systems, hemodialysis and blood purification equipment, respiratory and anesthesia devices, ICU and monitoring equipment, cardiovascular and interventional products, and in vitro diagnostics and laboratory instruments—along with hospitals, clinics, and home-care markets, which integrate these medical-grade rubber components into single-use disposables and reusable devices for infusion, blood management, drug delivery, monitoring, diagnosis, and therapy. The annual production capacity of a single-line Medical Grade Rubber is approximately 8k ton, with a gross profit margin of approximately 25%-40%.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2024, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

In the value chain, the upstream segment for medical-grade rubber consists of polymer and elastomer suppliers that provide medical-grade silicone rubbers, thermoplastic elastomers (TPE/TPU), butyl and halobutyl rubbers, EPDM, nitrile, fluororubbers, and synthetic polyisoprene, along with high-purity fillers such as silica, medical talc, and spherical silica, as well as medical-grade masterbatches, plasticizers, crosslinkers, and stabilizers. Some applications also require medical-grade stainless steel inserts, reinforcing fibers, and engineering plastics as substrates for overmolding or composite structures. The midstream comprises compounders and manufacturers of medical rubber products that operate in cleanroom environments, performing compounding, molding, extrusion, and post-curing to produce medical tubing, stoppers, plungers, O-rings, diaphragms, respirator masks, balloons, and valve components, often including rubber-to-metal or rubber-to-plastic bonded parts and multi-material assemblies; many also offer washing, sterilization, and sterile packaging. Downstream customers are a broad range of medical device and consumable manufacturers—including producers of infusion and injection systems, hemodialysis and blood purification equipment, respiratory and anesthesia devices, ICU and monitoring equipment, cardiovascular and interventional products, and in vitro diagnostics and laboratory instruments—along with hospitals, clinics, and home-care markets, which integrate these medical-grade rubber components into single-use disposables and reusable devices for infusion, blood management, drug delivery, monitoring, diagnosis, and therapy.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Medical Grade Rubber market?

What factors are driving Medical Grade Rubber market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Medical Grade Rubber market opportunities vary by end market size?

How does Medical Grade Rubber break out by Type, by Application?

This report presents a comprehensive overview of the global Medical Grade Rubber market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Synthetic Rubber
  • Natural Rubber

Segment by Materials

  • Butyl Rubber
  • Ethylene Propylene Rubber
  • Fluororubber
  • Silicone Rubber
  • Others

Segment by Size

  • 13mm
  • 15mm
  • 17mm
  • 20mm
  • Others

Segment by Application

  • Hospital
  • Clinic
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Medical Grade Rubber market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospital, Clinic, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Medical Grade Rubber Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 6.3%
Regional growth momentum
Market share by segment
Key metrics
Base value
$3.14B
2025
Forecast
$4.8B
2032
CAGR
6.3%
2025–2032
Régions
5
global
Key companies
ExxonMobilAVK GUMMIOomi Shima SangyoDupontDaikyo SeikoAPG PharmaDowElkem Silicones
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Synthetic RubberNatural Rubber
By Application
HospitalClinicOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Synthetic Rubber
  • 3.1.3 Natural Rubber
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospital
  • 4.1.3 Clinic
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 ExxonMobil
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 AVK GUMMI
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Oomi Shima Sangyo
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Dupont
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Daikyo Seiko
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 APG Pharma
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Dow
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Elkem Silicones
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Momentive Performance Materials
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Avantor
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Primasil
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Saint-Gobain
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Shin-Etsu Chemical
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Wacker Chemie
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 West Pharmaceutical Services
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 UD Pharma Rubber Products
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Sagar Rrubber
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Nipro
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Datwyler
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Aptar Pharma
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Huaren Pharmaceutical
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 HuaRun Technology
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 First Rubber Medical
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 Shandong Pharmaceutical Glass
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
  • 8.25 Ningbo Xingya Rubber & Plastic
  • 8.25.1 Company Overview
  • 8.25.2 Key Products & Segments
  • 8.25.3 Financial Performance (2023–2025)
  • 8.25.4 Business Strategy
  • 8.25.5 SWOT Analysis
  • 8.25.6 Strategic Implications (2026–2032)
  • 8.26 Jintai Industrial
  • 8.26.1 Company Overview
  • 8.26.2 Key Products & Segments
  • 8.26.3 Financial Performance (2023–2025)
  • 8.26.4 Business Strategy
  • 8.26.5 SWOT Analysis
  • 8.26.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Medical Grade Rubber market?
The global Medical Grade Rubber market is estimated at US$ 3.14 billion in 2025 (base year) and is projected to reach US$ 4.79 billion by 2032.
How fast is the Medical Grade Rubber market expected to grow?
The market is expected to grow at a CAGR of 6.3% from 2026 to 2032, expanding from US$ 3.14 billion in 2025 to US$ 4.79 billion in 2032, roughly 1.5 times its base-year value.
What does the Medical Grade Rubber market cover?
In 2024, global Medical Grade Rubber production reached approximately 720k tons, with an average global market price of around US$ 4200 per ton.
How is the Medical Grade Rubber market segmented by type?
By type, the market is segmented into Synthetic Rubber and Natural Rubber.
What are the key applications of Medical Grade Rubber?
Key applications covered include Hospital, Clinic and Others.
Which companies are profiled in the Medical Grade Rubber market report?
Key players profiled include ExxonMobil, AVK GUMMI, Oomi Shima Sangyo, Dupont, Daikyo Seiko, APG Pharma, Dow and Elkem Silicones, among 26 companies covered in total.
What geographies does the Medical Grade Rubber market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Medical Grade Rubber?
The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Who should buy the Medical Grade Rubber market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospital, Clinic and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Medical Grade Rubber market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3 500,00 $US
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.